Aprea Therapeutics (APRE)

• Market cap: $5.81M
• 1 day: -0.53%
• 5 days: -7.98%
• 1 month: -22.67%
• 3 months: -36.97%
• 6 months: -48.01%
• Year to date: -74.22%
• 1 year: -71.77%
• 5 years: -99.84%
• 10 years: -99.78%
• Sector: Healthcare
• Industry: Biotechnology

About: Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Employees: 8